QQQ   443.89 (-0.21%)
AAPL   171.00 (-1.33%)
MSFT   420.14 (-0.31%)
META   487.13 (-1.36%)
GOOGL   150.64 (-0.15%)
AMZN   180.16 (+0.18%)
TSLA   176.97 (-1.59%)
NVDA   906.19 (+0.41%)
NIO   4.54 (-2.78%)
AMD   180.69 (+0.61%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.75 (-1.17%)
CGC   8.96 (-6.18%)
GE   174.51 (-3.11%)
DIS   122.58 (+1.32%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.14 (+0.86%)
XOM   115.87 (+0.78%)
QQQ   443.89 (-0.21%)
AAPL   171.00 (-1.33%)
MSFT   420.14 (-0.31%)
META   487.13 (-1.36%)
GOOGL   150.64 (-0.15%)
AMZN   180.16 (+0.18%)
TSLA   176.97 (-1.59%)
NVDA   906.19 (+0.41%)
NIO   4.54 (-2.78%)
AMD   180.69 (+0.61%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.75 (-1.17%)
CGC   8.96 (-6.18%)
GE   174.51 (-3.11%)
DIS   122.58 (+1.32%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.14 (+0.86%)
XOM   115.87 (+0.78%)
QQQ   443.89 (-0.21%)
AAPL   171.00 (-1.33%)
MSFT   420.14 (-0.31%)
META   487.13 (-1.36%)
GOOGL   150.64 (-0.15%)
AMZN   180.16 (+0.18%)
TSLA   176.97 (-1.59%)
NVDA   906.19 (+0.41%)
NIO   4.54 (-2.78%)
AMD   180.69 (+0.61%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.75 (-1.17%)
CGC   8.96 (-6.18%)
GE   174.51 (-3.11%)
DIS   122.58 (+1.32%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.14 (+0.86%)
XOM   115.87 (+0.78%)
QQQ   443.89 (-0.21%)
AAPL   171.00 (-1.33%)
MSFT   420.14 (-0.31%)
META   487.13 (-1.36%)
GOOGL   150.64 (-0.15%)
AMZN   180.16 (+0.18%)
TSLA   176.97 (-1.59%)
NVDA   906.19 (+0.41%)
NIO   4.54 (-2.78%)
AMD   180.69 (+0.61%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.75 (-1.17%)
CGC   8.96 (-6.18%)
GE   174.51 (-3.11%)
DIS   122.58 (+1.32%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.14 (+0.86%)
XOM   115.87 (+0.78%)
NASDAQ:DRIO

DarioHealth (DRIO) Stock Price, News & Analysis

$1.46
-0.06 (-3.93%)
(As of 01:34 PM ET)
Today's Range
$1.45
$1.66
50-Day Range
$1.40
$2.55
52-Week Range
$0.68
$4.58
Volume
120,944 shs
Average Volume
134,638 shs
Market Capitalization
$39.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.03

DarioHealth MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
313.2% Upside
$6.03 Price Target
Short Interest
Bearish
4.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of DarioHealth in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.14) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

Medical Sector

820th out of 938 stocks

Surgical & Medical Instruments Industry

87th out of 97 stocks

DRIO stock logo

About DarioHealth Stock (NASDAQ:DRIO)

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DRIO Stock Price History

DRIO Stock News Headlines

DarioHealth earnings preview: what to expect
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
DarioHealth (DRIO) to Release Earnings on Thursday
DRIO Apr 2024 5.000 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
DarioHealth Corp. (DRIO)
See More Headlines
Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:DRIO
Employees
241
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$6.03
High Stock Price Target
$8.00
Low Stock Price Target
$4.10
Potential Upside/Downside
+277.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-62,190,000.00
Net Margins
-136.37%
Pretax Margin
-245.30%

Debt

Sales & Book Value

Annual Sales
$27.66 million
Book Value
$3.12 per share

Miscellaneous

Free Float
24,466,000
Market Cap
$43.55 million
Optionable
Optionable
Beta
1.70

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Erez  RaphaelMr. Erez Raphael (Age 51)
    CEO & Director
    Comp: $978.76k
  • Mr. Richard A. Anderson (Age 55)
    President
    Comp: $998.42k
  • Mr. Zvi Ben David (Age 63)
    CFO, Treasurer & Secretary
    Comp: $429.05k
  • Dov Oppenheim
    Co-Founder & Production Chief
  • Mr. Tomer Ben-Kiki (Age 53)
    Chief Operating Officer
  • Josh Fischer
    Senior Vice President of Operations & Compliance
  • Claudia Levi
    Content & Communications Manager
  • Mary Mooney
    Vice President of Marketing
  • Limor Drezner
    Chief People Officer
  • Mr. Jean Christophe Muyl
    Head of Commercialization North America

DRIO Stock Analysis - Frequently Asked Questions

Should I buy or sell DarioHealth stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings
or view top-rated stocks.

What is DarioHealth's stock price target for 2024?

2 equities research analysts have issued twelve-month target prices for DarioHealth's shares. Their DRIO share price targets range from $4.10 to $8.00. On average, they predict the company's stock price to reach $6.03 in the next twelve months. This suggests a possible upside of 313.2% from the stock's current price.
View analysts price targets for DRIO
or view top-rated stocks among Wall Street analysts.

How have DRIO shares performed in 2024?

DarioHealth's stock was trading at $1.72 at the start of the year. Since then, DRIO stock has decreased by 15.1% and is now trading at $1.4603.
View the best growth stocks for 2024 here
.

When is DarioHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our DRIO earnings forecast
.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.24. The company had revenue of $5.63 million for the quarter, compared to the consensus estimate of $5.95 million. DarioHealth had a negative trailing twelve-month return on equity of 43.03% and a negative net margin of 136.37%. During the same period in the prior year, the company posted ($0.71) EPS.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (8.58%), Appian Way Asset Management LP (4.86%), Clal Insurance Enterprises Holdings Ltd (3.22%), Vanguard Group Inc. (1.33%), Vanguard Group Inc. (1.33%) and Clarity Capital Partners LLC (0.63%). Insiders that own company stock include Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends
.

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does DarioHealth have any subsidiaries?
The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..
Read More
This page (NASDAQ:DRIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners